Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Down 6.3% – Should You Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s share price dropped 6.3% during trading on Monday . The company traded as low as $16.07 and last traded at $16.09. 1,724 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 370,734 shares. The stock had previously closed at $17.18.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DSNKY. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Performance

The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. The company has a market cap of $31.18 billion, a PE ratio of 19.47, a P/E/G ratio of 3.31 and a beta of -0.18. The firm’s 50-day simple moving average is $16.70 and its two-hundred day simple moving average is $17.43.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, research analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.